These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37108147)

  • 61. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
    MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
    Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.
    Alwhaibi A; Alsanea S; Almadi B; Al-Sabhan J; Alosaimi FD
    Aging Male; 2022 Dec; 25(1):101-124. PubMed ID: 35343371
    [No Abstract]   [Full Text] [Related]  

  • 63. Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function.
    Reiss AB; Saeedullah U; Grossfeld DJ; Glass AD; Pinkhasov A; Katz AE
    Clin Transl Oncol; 2022 May; 24(5):733-741. PubMed ID: 34743290
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.
    Ziaran S; Goncalves FM; Breza J
    World J Urol; 2013 Apr; 31(2):289-92. PubMed ID: 22898989
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of androgen deprivation therapy on metabolic markers and bioelectrical impedance analyze in prostate cancer patients.
    Çakıcı MÇ; Can B; Kazan Ö; Efiloğlu Ö; Şendoğan F; Uçar T; Turan T; Yıldırım A
    Rev Int Androl; 2022; 20(2):96-101. PubMed ID: 35115256
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study.
    Wong CHM; Xu N; Lim J; Feng KK; Chan WKW; Chan MTY; Leung SC; Chen DN; Lin YZ; Chiu PKF; Yee CH; Teoh JYC; Huang CY; Yeoh WS; Ong TA; Wei Y; Ng CF
    Prostate; 2023 Jun; 83(8):801-808. PubMed ID: 36938957
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study.
    Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
    Urology; 2016 Oct; 96():165-170. PubMed ID: 27402374
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
    Rijksen BLT; Pos FJ; Hulshof MCCM; Vernooij RWM; Jansen H; van Andel G; Wijsman BP; Somford DM; Busstra MB; van Moorselaar RJA; Kaa CAH; van Leenders GJLH; Hamberg P; van den Berkmortel F; Fütterer JJ; Kiemeney LA; van Oort IM; Aben KKH
    Eur Urol Focus; 2021 Mar; 7(2):332-339. PubMed ID: 31748122
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
    Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
    Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
    Nishiyama T
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
    Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
    JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer.
    Atalar K; Rajan P
    Nat Rev Urol; 2023 Jan; 20(1):3-4. PubMed ID: 36280769
    [No Abstract]   [Full Text] [Related]  

  • 76. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
    Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
    Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Antihormonal therapy in prostate cancer : Side effects].
    Ohlmann CH; Thelen P
    Urologe A; 2017 Apr; 56(4):465-471. PubMed ID: 28246761
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.
    Carneiro A; Sasse AD; Wagner AA; Peixoto G; Kataguiri A; Neto AS; Bianco BA; Chang P; Pompeo AC; Tobias-Machado M
    World J Urol; 2015 Sep; 33(9):1281-9. PubMed ID: 25387877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.